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Background: The VEGF Inhibition Study In Ocular Neovascularisation (VISION) reported 
the efﬁ  cacy of intravitreal (ITV) vascular endothelial growth factor (VEGF) inhibition with 
pegaptanib sodium (Macugen®) for the treatment of neovascular age-related macular degenera-
tion (AMD). This paper reports clinical experience with pegaptanib sodium for the treatment of 
occult or minimally classic choroidal neovascularization (CNV) due to AMD.
Material and methods: The study included 50 eyes (in 49 patients) with either occult 
CNV or minimally classic CNV secondary to neovascular AMD who were not eligible for 
photodynamic therapy (PDT). Study data were analyzed retrospectively. During the 6-month 
study, patients were administered an average 2.74 injections of 0.3 mg ITV pegaptanib sodium. 
Angiography and optical coherence tomography (OCT) examinations were carried out and 
intraocular pressure (IOP) and visual acuity (VA) were measured at baseline, at 3 months and 
at 6 months. An eye examination was performed and VA was measured the 2 days following 
treatment and then again at weeks 4–6, and at 3 and 6 months. OCT, VA, and IOP were also 
assessed at 1 month.
Results: ITV pegaptanib sodium was well tolerated and no treatment complications arose. Mean 
VA was measured as: 0.37 ± 0.24 at baseline; 0.37 ± 0.25 at 1 month; 0.37 ± 0.25 at 3 months 
and 0.40 ± 0.26 at 6 months. VA was stabilized in approximately 90% of eyes treated with 
pegaptanib sodium. OCT examination showed a minimal change in central retinal thickness 
(CRT) during the course of the study, from 251.19 μm at baseline to 251.63 μm at 6 months. 
No elevation in IOP was measured during treatment at 4–6 months in patients receiving pegap-
tanib sodium.
Conclusions: ITV therapy with pegaptanib sodium for occult and minimally classic CNV 
secondary to neovascular AMD offered good efﬁ  cacy with a favorable adverse events 
proﬁ  le. The majority of patients showed stabilization in all assessed parameters. In clinical 
practice, careful consideration should be given to the use of nonselective VEGF inhibition 
in patients with a high cardiovascular risk proﬁ  le or in those with a history of thromboem-
bolic events.
Keywords: Intravitreal (ITV) injection, age-related macular degeneration (AMD), choroidal 
neovascularization (CNV), anti-VEGF therapy, pegaptanib sodium
Introduction
Age-related macular degeneration (AMD) is one of the most common causes of irre-
versible, severe vision loss in the elderly population of Western societies, often having 
a signiﬁ  cant effect on quality of life (Bird 1996; Mitchell and Bradley 2006).
Neovascular AMD is characterized by choroidal neovascularization (CNV). The 
pathophysiology of neovascular AMD is complex and involves numerous processes. 
Vascular endothelial growth factor (VEGF) plays a key role in many of these processes Clinical Ophthalmology 2008:2(2) 254
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(Adamis and Shima 2005). VEGF is a stimulator of the 
angiogenesis associated with CNV: it plays a fundamental 
role in the stimulation of cell proliferation of the endothe-
lium, increases vascular permeability and has a chemotactic 
effect on macrophages. Yet VEGF also induces blood vessel 
growth and is necessary for the preservation of normal ves-
sels and vascular function (Thakker et al 1999; Tilton et al 
1999; Bernatchez et al 2002).
Pegaptanib sodium (Macugen®, [OSI] Eyetech Pharma-
ceuticals, Pﬁ  zer) was the ﬁ  rst anti-VEGF agent licensed for 
the treatment of neovascular AMD. It is an oligonucleotide 
that functions as an aptamer (from the Latin “aptus”, to 
match/ﬁ  t; and the Greek “meros”, part) and, similar to an 
antibody, speciﬁ  cally blocks the activity of the VEGF165 iso-
form that is largely responsible for the formation of the CNV 
associated with neovascular AMD (Ishida et al 2003).
The efﬁ  cacy of pegaptanib sodium was investigated in 
the VEGF Inhibition Study In Ocular Neovascularization 
(VISION): 2 concurrent prospective, randomized, double-
blind, multicenter, dose-ranging, controlled clinical trials 
(Gragoudas et al 2004). VISION deﬁ  ned broad inclusion 
parameters, including patients with all angiographic sub-
types (predominant classic, minimally classic and occult 
lesions) and with visual acuity (VA) between 20/320 and 
20/40. Patients were randomized to receive intravitreal 
(ITV) injections of pegaptanib sodium (0.3 mg, 1.0 mg, 
or 3.0 mg) or sham injection in 1 eye every 6 weeks over 
a period of 48 weeks. The study included all patients with 
classic and occult CNV, despite the fact that patients with 
predominantly classic lesions could have received addi-
tional photodynamic therapy (PDT) if it was considered 
appropriate by the investigator. The primary endpoint was 
the proportion of patients who had lost fewer than 15 let-
ters (3 lines) of VA at 54 weeks and at years 2 and 3 (VA 
stabilization was deﬁ  ned as a loss of fewer than 15 letters 
over the duration of the trial).
VA stabilization was achieved in approximately 70% 
of patients administered pegaptanib sodium compared 
with 55% in the control group (p  0.001). VISION 
concluded that pegaptanib sodium was effective in all 
subtypes of neovascular AMD, including predominant 
classic, minimally classic, and occult lesion types. The 
treatment beneﬁ  t was not only noted after 54 weeks, but 
also at all examinations carried out during years 1 and 2 
of the study (Gragoudas et al 2004; D’Amico et al 2006). 
During the second year, the therapeutic effect was main-
tained through administration of 6-weekly ITV injections 
(D’Amico et al 2006).
In this review, we report the ﬁ  ndings of our clinical 
experience with the agent over a period of 6 months at our 
clinic in Germany.
Material and methods
The data reported were attained through clinical experience 
with compassionate use pegaptanib sodium in 50 eyes (of 
49 patients) with progressive vision loss due to neovascular 
AMD, before and after the agent’s approval in the European 
Union (EU).
At assessment, carried out up to a month prior to treatment 
initiation, patients were deemed eligible for treatment with 
pegaptanib sodium if they reported acute visual impairment 
or metamorphopsia and demonstrated occult or minimally 
classic CNV. Of the 50 eyes treated with pegaptanib sodium, 
39 had occult CNV and 11 had minimally classic CNV. 
Most patients were female: 32 women compared with only 
17 men, and had an average age of 78 years (age range 
of 54–87 years). Twenty-two of the patients had received 
previous treatment during the 3- to 6-month period prior to 
the ﬁ  rst study injection. Of those 22 patients: 8 patients had 
received triamcinolone monotherapy; 1 had been treated with 
PDT monotherpay; 8 with PDT in combination with triam-
cinolone; 2 patients had received ITV injections of tissue 
plasminogen activator r-TPA and gas, and 3 had undergone 
cataract operations.
Baseline assessments included best-corrected VA 
(BCVA), slit lamp examination of the anterior segment, fun-
duscopy, OCT, and measurement of IOP. The examinations 
were repeated at 4–6 weeks, at 3 months and at 6 months 
after the ﬁ  rst injection. IOP and slit lamp examinations were 
also performed on days 1 and 2 post-injection. Fluorescein 
angiography (FA) of the ocular fundus was performed at 
baseline, post injection, at 3 months, and at 6 months. Base-
line CRT and volume were assessed with OCT and compared 
with measurements taken at 1 month, at 3 months, and at 
6 months post injection. All patients were monitored for a 
period of 6 months.
All patients received an ITV injection of pegaptanib 
sodium (0.3 mg). Indicators of the need for re-injection were 
increased intra-retinal ﬂ  uid or a rise in CRT of more than 
100 μm (measured by OCT), a decrease in VA or angiograph-
ically persisting leakage. An average of 2.74 injections were 
administered per patient; the majority of patients received 1 
(15 patients) or 2 (17 patients) injections, but 8 patients re-
ceived 3 injections, 5 received 4 injections, and 5 patients 
received 5 injections. The high percentage of patients that 
received only 1 or 2 injections during the 6-month follow up Clinical Ophthalmology 2008:2(2) 255
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period of this study was a consequence of the need to apply 
for reimbursement for each separate injection at the outset 
of the study. As a result, a standardized injection regimen 
could not be established in some cases. Patients were deemed 
ineligible for treatment if they had maculopathy originating 
from a condition other than AMD, or if they exhibited signs 
of any acute ocular infection.
The ITV injection of pegaptanib sodium (0.3 mg) was 
performed in accordance with the guidelines for ITV injec-
tion published by the Macula Committee of the German 
Ophthalological Society (DOG) and the Professional Asso-
ciation of Ophthalmologists of Germany (BVA) (DOG and 
BVA 2006). Before injection administration, the eye was 
washed with povidone iodide (5%) and the ciliae and lid 
regions were then wiped, also with povidone iodine (5%). 
The drape (as used for intraocular intervention) was applied, 
a speculum was inserted, and paracentesis was performed 
in all cases to reduce the intraocular volume. After dislo-
cation of the conjunctivae (with the use of a sterile pad to 
avoid penetration of the conjunctiva and sclera at the same 
location), pegaptanib sodium (0.09 mL) was injected at a 
distance of 3.5 mm from the limbus. Antibiotic eye drops 
were then given.
Results
The 6-month results from the 50 treated eyes were analyze 
retrospectively. Mean VA at baseline was 0.37 ± 0.24 and 
remained stable at 1 month and 3 months (0.37 ± 0.25). At 6 
months, however, the mean BCVA had improved to 0.40 ± 
0.26 (see Figure 1).
VA measurements at 1 month post injection revealed that: 
2 patients (4%) had lost 3 or more lines; 46 patients (92%) 
had stabilized (had lost or gained less than 3 lines); and 2 
patients (4%) had gained more than 3 lines (see Figure 2a). 
VA measurements 3 months post injection demonstrated that: 
1 patient (2%) had lost 3 or more lines; 48 patients (92%) had 
stabilized ±3 lines; and 1 patient (4%) had gained more than 
3 lines (see Figure 2b). At ﬁ  nal measurement, 6 months post 
injection: only 1 patient (2%) had lost more than 3 lines; 45 
patients (90%) had stabilized within ±3 lines; and 4 patients 
(8%) had experienced an increase in VA of more than 3 lines 
(see Figure 2c).
Mean CRT, measured by OCT examination, at baseline 
was 251.19 ± 75.83 μm. Post-injection measurements or CRT 
recorded mean values of: 252.00 ± 71.27 μm at 1 month; 
247.38 ± 66.28 μm at 3 months; and 251.63 ± 68.23 μm at 
6 months (see Figure 3).
Semi-quantitative evaluation of the angiographic images 
revealed stabilization or reduction in lesion size or exuda-
tion. During the 6-month period following ﬁ  rst ITV admin-
istration of pegaptanib sodium, no conversion of occult 
CNV into a predominantly classic CNV was observed. One 
patient had an IOP of more than 21 mmHg when measured 
1 month post-injection, but this returned to normal after 
management with topical anti-glaucoma therapy. No serious 
post-injection complications (eg, intraocular bleeding, 
retinal detachment, endophthalmitis, or cataract progression) 
were observed.
The following case study offers an illustration of the 
approach to treatment taken in the study.
Figure 1 Mean visual acuity over time (n = 50).
Figure 2a Change in visual acuity after 1 month (n = 50).
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Conclusion
This paper is a report of our clinical experience with pegap-
tanib sodium for the treatment of neovascular AMD. As 
there were no approved therapies available for the treatment 
of occult and minimally classic CNV in 2005, patients who 
were administered pegaptanib sodium for treatment of neo-
vascular AMD in September 2005 ahead of its EU licence 
did so through the compassionate use program (DOG and 
BVA 2006). Eleven patients at our clinic were treated with 
pegaptanib sodium in advance of its licence being granted 
for the treatment of neovascular AMD in Germany in May 
2006; 8 of those patients received more than 1 injection 
of the agent.
A total of 35 eyes were treated with multiple injections 
in the observation period. There was good clinical accep-
tance of the drug with no observation of severe side effects, 
such as endophthalmitis or retinal detachment. Re-treat-
ment was also well tolerated among the patient group. One 
patient developed an elevation in their IOP after the ﬁ  rst 
injection, but this was quickly and successfully managed 
with the use of topical anti-glaucoma medication. In total, 
patients were observed for a period of 6 months and some 
(4%–8%) beneﬁ  ted from an improvement in their vision 
of more than 3 lines. In comparison to the VISION trial 
there was a higher percentage of patients with stabilization 
of VA at the endpoint of our investigation (at month 6). 
Figure 2b Change in visual acuity after 3 months (n = 50).
Figure 2c Change in visual acuity after 6 months (n = 50).
Case study
At baseline, Patient A complained of visual impairment and 
metamorphopsia in their better (left) eye. The right eye had a 
VA of approximately 0.03 and featured macular scarring due 
to neovascular AMD, and the left-eye had VA of 0.20 (see 
Figure 4). VA measured after the ﬁ  rst ITV injection of pegap-
tanib sodium was 0.40, which increased to 0.63 after 3 injec-
tions and stabilized at 0.60 after 5 injections. Figure 5 shows 
the angiographic ﬁ  ndings after 5 injections with pegaptanib 
sodium (0.3 mg). After only the second injection Patient A 
reported that they were able to read and drive again.
Figure 3 Central retinal thickness as measured with optical coherence tomography 
over time.
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No sub-analysis was performed to determine any possible 
relationship between lesion size and visual outcome. The 
OCT assessment of CRT at 1, 3, and 6 months post injec-
tion showed little change (see Figure 3). No correlation was 
observed between CRT and VA.
During the period of observation, 5 patients switched 
therapy from selective anti-VEGF therapy with pegap-
tanib sodium to treatment with unselective anti-VEGF 
agents because of a lack of efﬁ  cacy. No further visual 
impairment was observed in these patients. The effi-
cacy of ranibizumab (Lucentis®, Genentech, Inc) for the 
treatment of neovascular AMD has been investigated in 
prospective, randomized, placebo-controlled multi-center 
studies: Minimally Classic/Occult Trial of the Anti-VEGF 
Antibody Ranibizumab in the Treatment of Neovascular 
Age-Related Macular Degeneration (MARINA), and 
Anti-VEGF Antibody for the Treatment of Predominantly 
Classic Choroidal Neovascularization in Age-Related 
Macular Degeneration (ANCHOR). The data showed that 
BCVA stabilization was achieved in approximately 90% 
of patients (stabilization was deﬁ  ned as a loss of less than 
3 lines on the Early Treatment Diabetic Retinopathy Study 
[ETDRS]) chart (Brown et al 2006; Rosenfeld et al 2006a, 
b). No such large-scale randomized clinical trials have been 
carried out to assess the efﬁ  cacy of bevacizumab (Avastin®, 
Genentech, Inc) for ITV administration for neovascular 
AMD and the agent remains unlicensed for this indication 
at this time. However, the literature does report the ﬁ  ndings 
of retrospective case control studies of up to 266 patients 
in which a decrease of CRT and an improvement of VA 
was reported in up to 38% of patients following treatment 
with ITV bevacizumab for neovascular AMD (Avery et al 
2006; Spaide et al 2006).
ITV anti-VEGF therapy requires periodic injections 
and, consequently, re-treatment tolerability is important. 
Our experience of pegaptanib sodium indicates that repeti-
tive treatment is well tolerated by patients. At the time of 
writing, there are currently no consistent recommendations 
to advise on the exact pre-treatment diagnostic measures, 
follow-up examinations (eg, single OCT vs OCT plus 
Figure 4 Patient A: aged 75 years, results of funduscopy and late-phase angiography assessment at baseline.   Acute left-eye visual impairment and metamorphopsia.
Left eye: V A = 0.20 Right eye: V A = 0.03Clinical Ophthalmology 2008:2(2) 258
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angiography), or on the duration and frequency of follow-up 
assessments. In addition, it still remains unclear whether it 
is necessary to administer repeat injections every 6 weeks 
after initiation of a therapy for a 2-year period, or if clinical 
judgement can be used to determine whether the interval 
between successive injections can be prolonged. Two 
recent trials investigated a loading strategy for ranibizumab 
therapy – the Prospective Optical Coherence Tomography 
(OCT) Imaging of Patients with Neovascular Age-Related 
Macular Degeneration (AMD) Treated with Intra-Ocular 
ranibizumab (PrONTO), and a Phase IIIb, multicenter, ran-
domized, double-masked, sham Injection-controlled study 
of the Efﬁ  cacy and safety of Ranibizumab in subjects with 
subfoveal CNV with or without classic CNV secondary 
to AMD (PIER). The approach involved the administra-
tion of 3 injections with subsequent re-treatment being 
administered as needed. The strategy appeared to result in 
superior treatment outcomes than those achieved when there 
are prolonged intervals between the re-treatment injections 
(Rosenfeld et al 2006c).
Pegaptanib sodium was the first anti-VEGF agent 
approved for ITV administration for neovascular AMD. The 
VA results of the VISION study are clearly inferior to those 
of the MARINA and ANCHOR studies with ranibizumab. 
At the time of writing, therefore, pegaptanib sodium is con-
sidered second-line therapy. However, VA efﬁ  cacy is only 
one of the clinical considerations that must be taken into 
account. In our study, the safety proﬁ  le of pegaptanib sodium 
during the observation period was good; no relevant systemic 
or ocular side effects were noted. Cardiovascular incidents 
and overall mortality in the pegaptanib sodium group were 
comparable to those of the sham injection group. In addition, 
a separate trial looking at ITV pegaptanib sodium injections 
over a 2-year period concluded that there was no clinical or 
angiographical-proven retinal or choroidal damage detectable 
(Gragoudas et al 2004). It should also be noted that there 
are currently no data concerning the safety of bevacizumab in 
the ocular environment. Systemic administration of the agent, 
as licensed for the treatment of colorectal cancer, has been 
noted to cause an elevation in the incidence of thrombem-
bolic events, as well as gastrointestinal perforations (Roche 
Products Limited 2007).
The Safety Assessment of Intravitreal Lucentis fOR AMD 
(SAILOR) study investigated the safety proﬁ  le of different 
dosages of ITV ranibizumab. After a follow-up period of 
230 days, an elevated incidence of (cerebral) strokes was 
found in the study arm randomized to receive 0.5 mg ITV 
ranibizumab compared with those randomized to 0.3 mg 
ranibizumab. Patients with a history of apoplexy seemed to 
have a higher risk of apoplectic stroke. No difference was 
found for myocardial infarction or overall mortality (Dafer 
et al 2007). These data are of particular interest when con-
sidered in conjunction with animal studies that found ITV 
administration resulted in the substance being detectable 
systemically, indicating systemic bioavailability and a need 
to assume the possibility of associated side effects (Drolet 
et al 2000). This argument is further substantiated by reports 
in the literature of incidents where therapeutic effects were 
observed not only in the treatment eye, but also in the fellow 
eye (Mennel et al 2007).
The approval studies for pegaptanib sodium and ranibi-
zumab clearly show that multiple injections are necessary 
over a prolonged period of time to maintain the effective-
ness of therapy. It is also noteworthy that the implications 
of a permanent ocular or systemic blockade of all VEGF-A 
Figure 5 Patient A: results of left-eye optical coherence tomography and late-phase 
angiography after 5 injections of pegaptanib sodium.
Left eye VA = 0.60Clinical Ophthalmology 2008:2(2) 259
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isoforms remain unclear at this time. In a clinical setting, 
therefore, it is critical to consider the potential systemic 
side effects of repeated treatments with nonselective VEGF 
inhibitors in those patients with a high cardiovascular risk 
proﬁ  le or with a history of thromboembolic events.
References
Adamis AP, Shima TS. 2005. The role of vascular endothelial growth factor 
in ocular disease. Retina, 25:111–18.
Avery RL, Pearlman J, Pieramici DJ, et al. 2006. Intravitreal bevacizumab 
(Avastin) in the treatment of proliferative diabetic retinopathy. 
Ophthalmology, 113:1695.e1–15.
Bernatchez PN, Rollin S, Soker S, et al. 2002. Relative effects of VEGF-
A and VEGF-C on endothelial cell proliferation, migration and PAF 
synthesis: Role of neuropilin-1. J Cell Biochem, 85:629–39.
Bird AC. 1996. Age-related macular disease. Br J Ophthalmol, 80:1–2.
Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. 2006. 
Ranibizumab versus verteporﬁ  n for neovascular age-related macular 
degeneration. N Engl J Med, 355:1432–44.
Dafer RM, Schneck M, Friberg TR, Jay WM. 2007. Intravitreal ranibizumab 
and bevacizumab: a review of risk. Semin Ophthalmol, 22:201–4.
D`Amico DJ. 2005. Results of the second year of Macugen for the treatment 
of neovascular AMD (V .I.S.I.O.N). Abstract presented at the American 
Society of Retinal Specialists Meeting, Montreal, 16–20 July 2005.
D'Amico DJ, Masonson HN, Patel M, et al. 2006. Pegaptanib sodium for 
neovascular age-related macular degeneration: two-year safety results 
of the two prospective, multicenter, controlled clinical trials. Ophthal-
mology, 113:992–1001.
Drolet DW, Nelson J, Tucker CE, et al. 2000. Pharmacokinetics and safety 
of an anti-vascular endothelial growth factor aptamer (NX1838) fol-
lowing injection into the vitreous humor of rhesus monkeys. Pharm 
Res, 17:1503–10.
Gragoudas ES, Adamis AP, Cunningham ET Jr, et al; VEGF Inhibition 
Study in Ocular Neovascularization (VISION) Clinical Trial Group. 
2004. Pegaptanib for neovascular age-related macular degeneration. 
N Engl J Med, 351:2805–16.
Ishida S, Usui T, Yamashiro K, et al. 2003. VEGF164-mediated inﬂ  ammation 
is required for pathological, but not physiological, ischemia-induced 
retinal neovascularization. J Exp Med, 198: 483–9.
Mennel S, Callizo J, Schmidt JC, et al. 2007. Acute retinal pigment epithe-
lial tear in the untreated fellow eye following repeated bevacizumab 
(Avastin) injections. Acta Ophthalmol Scand, 85:689–90. Epub 2007 
Apr 2.
Mitchell J, Bradley C. 2006. Quality of life in age-related macular degenera-
tion: a review of the literature. Health Qual Life Outcomes, 21; 4:97.
Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. 2006a. 
Ranibizumab for neovascular age-related macular degeneration. N Engl 
J Med, 355:1419–31.
Rosenfeld PJ, Rich RM, Lalwani GA. 2006b. Ranibizumab: Phase III clinical 
results. Ophthalmol Clin North Am, 19:361–72.
Rosenfeld PJ, Fung AE, Lalwani GA, et al. 2006c. Visual acuity outcomes 
following a variable-dosing regimen for ranibizumab (Lucentis) in 
neovascular AMD: the PrONTO Study. Abstract presented at the Asso-
ciation for Research in Vision and Ophthalmology, Fort Lauderdale, 
Florida, 30 April – 4 May 2006; Abstract 2958.
Spaide RF, Laud K, Fine HF, et al. 2006. Intravitreal bevacizumab treat-
ment of choroidal neovascularization secondary to age-related macular 
degeneration. Retina, 26:383–90.
Macula Committee of the German Ophthalological Society (DOG) and the 
Professional Association of Ophthalmologists of Germany (BVA). 
2006. Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei 
der neovaskulären altersabhängigen Makuladegeneration (Comments 
on current therapeutic possibilities for neovascular age-related macular 
degeneration). Klin Monatsbl Augenheikd, 223:271–8.
Tilton RG, Chang KC, LeJeune WS, et al. 1999. Role for nitric oxide in the 
hyperpermeability and hemodynamic changes induced by intravenous 
VEGF. Invest Ophthalmol Vis Sci, 40:689–96.
Thakker GD, Hajjar DP, Muller WA, et al. 1999. The role of phospati-
dylinositol 3-kinase in vascular endothelial growth factor signaling. 
J Biol Chem, 274:10002–7.
Roche Products Limited. 2007. Summary of Product Characteristics: 
Avastin 25 mg/ml concentrate for solution for infusion. Last updated 
12 November 2007.